Introduction {#S1}
============

Visuospatial dysfunction (VSD) is a common clinical symptom used for the diagnosis of cognitive impairment or dementia due to Alzheimer's disease (AD) ([@B19]; [@B13]). Furthermore, VSD is the central symptom for the diagnosis of dementia with Lewy bodies (DLB) ([@B18]). DLB is the second most-common type of degenerative dementia and previous studies have provided evidence of VSD in patients with DLB ([@B18]). Previous studies assessing VSD in patients with dementia revealed several important clinical information with particular relevance for its connection to DLB. For example, salient and initial VSD are essential for the diagnosis of DLB ([@B18]). Besides, well-formed, detailed, and complex visual hallucinations (VH) are among the core diagnostic features for DLB and this striking feature starts early in the disease ([@B18]). The presence of VSD may also identify patients whose syndrome is driven by DLB rather than by AD pathology ([@B10]). The presence of early and severe VSD increases the likelihood that patients will develop prototypical DLB syndrome ([@B10]). In the early stages of dementia, VSD is more profound in DLB than in AD but memory retrieval deficit is more prominent in AD than in DLB ([@B28]). Studies of VSD mainly focused on the clinical performance of perception of locations or objects ([@B5]). Unlike these types of performance, visuomotor dysfunction manifests in goal-directed or visual-guided behavior and is also regarded as part of the visuospatial system of the brain ([@B5]). Visuomotor function is compromised in AD compared to normal elderly ([@B26]; [@B8]; [@B11]). Pathophysiological studies of visuomotor dysfunction revealed that reciprocal communication between hippocampal, parietal, and frontal brain regions play an important role in transforming visual-spatial information into goal-directed actions ([@B8]; [@B11]). Disrupting these connections could affect the skills for activities of daily living ([@B11]). Several studies using visuospatial/visuomotor function tests of the performance of visual recognition, visual discrimination, visual attention, or visuo-perceptive integration in DLB compared to AD revealed that these skills are impaired in DLB compared with AD ([@B23]; [@B27]; [@B15]).

Based on these studies and diagnostic criteria, VSD including impairment of visuomotor skills is important for the diagnosis of dementia including AD and DLB. Therefore, a simple screening tool for VSD would be useful in a clinical setting but VSD assessment in common informant-based dementia assessment tools is still lacking and unable to satisfy the clinical requirements. For example, in the Clinical Dementia Rating (CDR) scale, evaluation of VSD is embedded in the domain of orientation and only a few questions address navigating function ([@B10]) but no question addresses visuomotor function. Impaired visuomotor skills are also important in other domains that are characteristic of DLB or posterior cortical atrophy (PCA) ([@B19]; [@B18]). Furthermore, frequently- used cognitive screening tests for dementia or cognitive impairment, for example, Mini-Mental Status Examination (MMSE), Cognitive Abilities Screening Instrument (CASI), and Montreal Cognitive Assessment (MoCA), also do not include visuomotor skills ([@B7]; [@B25]; [@B2]).

To solve this problem, the initial aim of our study was to validate a novel VSD questionnaire that contained frequently-asked questions or common complaints of visuospatial and visuomotor symptoms obtained from caregivers or patients. In addition, we intended to use the simple questionnaire for investigating different presentations of VSD among the non-demented (ND) elderly, patients with neurodegenerative disorders including AD, DLB, or other disorders. Furthermore, during the consecutive data collection, the embedded auto-judgment program in the questionnaire continued to revise machine learning techniques to improve the ability of differential diagnosis of severity and subtypes of dementia.

Materials And Methods {#S2}
=====================

This is a sub-study of the History-based Artificial Intelligent Clinical Dementia Diagnostic System (HAICDDS) project which is currently used as a registration platform in the Show Chwan Health System. Before the starting of the study, twenty-six participants with their informants were interviewed by neuropsychologists from 3 centers of the health system and the reproducibility was investigated using the interrater reliability analysis. The results revealed a high intra-class correlation coefficient of 0.830. The detailed procedure of this project was described in our previous reports ([@B16]; [@B3], [@B4]). In this study, we analyzed the data of individuals with normal cognition (NC), mild cognitive impairment (MCI), and dementia due to DLB or AD.

Diagnosis of AD or DLB {#S2.SS1}
----------------------

The diagnosis of DLB was made according to the revised consensus criteria for probable DLB developed by the fourth report of the DLB consortium ([@B18]). According to these criteria, at least two of the following core features including fluctuation of cognition, VH, parkinsonism, and REM sleep behavior disorder (RBD) or one core features plus at least one indicative biomarker including abnormal dopamine transporter imaging (DaTabN), abnormal ^123^I-metaiodobenzylguanidine (MIBG), and REM sleep without atonia (RSWA) were necessary for the diagnosis of probable DLB. AD patients were diagnosed according to the criteria for probable AD developed by the National Institute on Aging and Alzheimer's Association Workgroup (NIA-AA) ([@B13]).

Diagnosis of Non-demented Control (NDC) or Different Stages of Dementia {#S2.SS2}
-----------------------------------------------------------------------

For the diagnosis of NDC, patients should have NC or MCI. NC was diagnosed with a global CDR ([@B20]) score of 0. MCI was diagnosed based on the criteria for MCI of the National Institute on Aging and Alzheimer's Association Workgroup on 2011 ([@B1]) as a change in cognition with impairment in one or more cognitive domains but no evidence of impairment in social or occupational functioning with a CDR score of 0.5 and the sum of boxes of CDR (CDR-SB) 0.5--4.0 ([@B22]). The diagnosis of dementia was made according to the criteria for dementia developed by the NIA-AA ([@B13]). Participants with dementia had impairments in two or more cognitive domains as well as a decline in daily functions (at least one of the domains of community affairs, home hobbies, and personal care with a CDR ≥ 0.5). Dementia severity was defined by a global CDR scale. A global CDR score of 0.5, 1, 2, and 3 was defined as very mild, mild, moderate, and severe dementia, respectively ([@B20]).

Procedure of the Study {#S2.SS3}
----------------------

This is a retrospective analysis of data from the HAICDDS which is currently applied in three centers in Taiwan (two in central Taiwan and one in southern Taiwan). In the database, daily function was assessed using the Instrumental Activities of Daily Living (IADL) Scale ([@B14]). Cognitive function was assessed using the Cognitive Abilities Screening Instrument (CASI) ([@B25]) and the Montreal Cognitive Assessment (MoCA) ([@B2]). Cognitive tests for all patients were performed by trained neuropsychologists. VSD was assessed using the visuospatial subscale of CASI (CASI-Draw, total score 0--10), of MoCA (MoCA-VS, total score 0--5), and of the HAICDDS (HAI-VSQ, total score 0--12) which includes 7 visuospatial/visuomotor function questions (The original Chinese version of the questionnaire with tentative English translation is shown in [Appendix Table A1](#A4){ref-type="table"}). VSD of NDC, AD, and DLB were analyzed and compared. In performing HAICDDS, informants of the participants were interviewed by a well-trained neuropsychologist and were requested to fill out the original structured questionnaire to determine the severity of dementia or cognitive impairment.

Statistics {#S2.SS4}
----------

The Chinese version of SPSS 22.0 for Windows (IBM, SPSS Inc., Chicago) was used for statistical analyses. For the determination of cut-off score for the differentiation from DLB to NCD, we want to maximize both the sensitivity and specificity therefore, the Youden's index was applied, which is maximum = sensitivity + specificity − 1. Comparisons of demographic data, neuropsychological tests, sum of boxes of CDR (CDR-SB), IADL, MoCA, MoCA-VS, CASI, CASI-Draw, HAI-VSQ, and sum of score of the Neuropsychiatric Inventory (NPI-sum) ([@B6]) were compared between the different groups and analyzed using independent t-tests or one-way ANOVA with either Bonferroni or Dunnett T3 *post hoc* analysis according to the homogeneity of variance. Gender and DLB clinical features (fluctuation, VH, RBD, Parkinsonism, and abnormal dopamine transporter imaging) ([@B18]) were analyzed with the chi-square test. Multivariable risk estimates (OR) for each question in HAI-VSQ, CASI-Draw, and MoCA-VSQ were adjusted for age, gender, education, and cognitive function and compared between AD/NDC, DLB/NDC, and DLB/AD groups. Pearson correlation coefficients were derived between age, education, gender, CDR-SB, IADL, CASI, MoCA, and NPI of the different diagnostic tools for VSD.

Ethical Consideration {#S2.SS5}
---------------------

The participants were selected from a register-based database of Show Chwan Health System. The study design was retrospective and the data were analyzed anonymously. The Committee for Medical Research Ethics of Show Chwan Memorial Hospital reviewed the project and the Data Inspectorate approved the study.

Results {#S3}
=======

A total of 440 individuals were studied, including 154 NDC, 229 AD, and 57 DLB participants. One or more visuospatial symptoms were reported in 31.2% of NC, 81.7% of AD, and 91.2% of DLB participants. Mean age of the NDC group (71.3 ± 9.2) was significantly smaller than those of DLB (81.3 ± 7.0) or AD (80.2 ± 7.2) using one-way ANOVA (*F* = 65.58; *p* \< 0.001). After adjustment for age, the dementia groups showed impaired responses to all questions compared to the NDC group (all *p* \< 0.001). Compared to NDC (0.4 ± 0.6) or AD (2.0 ± 2.2), the DLB (3.3 ± 2.2) group showed significantly increased total score of the HAI-VSQ after adjustment for age (both *p* \< 0.001). Using HAI-VSQ, a cutoff score ≥ 2 was useful for the discrimination of VSD in DLB and NDC with a sensitivity of 0.77, a specificity of 0.94, and an AUC of 0.91 ([Figure 1](#F1){ref-type="fig"}).

![Receiver--operating characteristic curves (ROC) of the HAI-VSQ for the discrimination of VSD in DLB and NDC. A cutoff score ≥ 2 was useful with a sensitivity of 0.77, a specificity of 0.94, and an AUC of 0.91.](fnins-14-00044-g001){#F1}

Additionally, the DLB group demonstrated higher CDR-SB, NPI, and Lewy body clinical features, including fluctuation of cognition, VH, Parkinsonism, and RBD after adjustment for age (all *p* \< 0.001). The DLB group also demonstrated significant lower IADL, CASI, and MoCA compared to NDC or AD participants after adjustment for age (all *p* \< 0.001). Compared to NDC participants, AD patients showed significantly higher CDR-SB, were proportionally more often female, had a significantly higher total score of the HAI-VSQ, NPI, and significantly higher fluctuation after adjustment for age (all *p* \< 0.001). The AD patients also demonstrated lower education, IADL, MoCA, and CASI compared to NDC participants ([Table 1](#T1){ref-type="table"}).

###### 

Comparison of demographic data among the NDC (*N* = 154), AD (*N* = 229), and DLB (*N* = 57) participants.

                             NDC mean (*SD*)   AD mean (*SD*)   DLB mean (*SD*)   AD vs. NDC OR, *p*-value   DLB vs. NDC *p*-value   DLB vs. AD *p*-value
  -------------------------- ----------------- ---------------- ----------------- -------------------------- ----------------------- ----------------------
  Age, year                  71.3 (9.2)        80.2 (7.2)       81.3 (7.0)        NA                         NA                      NA
  CDR-SB                     0.8 (0.7)         7.0 (4.6)        10.3 (5.3)        11.25, \< 0.001            4.78, \< 0.001          1.15, \< 0.001
  Female, N (%)              81 (52.6)         151 (65.9)       32 (56.1)         1.88, 0.010                0.92, NS                0.67, NS
  Education                  7.1 (5.1)         4.1 (4.4)        3.2 (3.7)         0.93, 0.003                0.90, 0.027             0.95, NS
  HAI-VSQ                    0.4 (0.6)         2.0 (2.2)        3.3 (2.2)         3.68, \< 0.001             5.62, \< 0.001          1.26, \< 0.001
  IADL                       7.5 (1.0)         2.3 (2.6)        1.2 (2.1)         0.31, \< 0.001             0.37, \< 0.001          0.78, 0.003
  MoCA                       19.1 (6.1)        6.8 (5.1)        5.8 (4.8)         0.75, \< 0.001             0.70, \< 0.001          0.95, NS
  CASI                       79.4 (12.2)       41.8 (22.8)      39.7 (21.8)       0.90, \< 0.001             0.89, \< 0.001          0.99, NS
  NPI                        3.1 (5.0)         5.4 (7.7)        16.0 (16.4)       1.09, \< 0.001             1.23, \< 0.001          1.10, \< 0.001
  Fluctuation, N (%)         2 (1.3)           36 (15.7)        37 (64.9)         12.87, \< 0.001            135.9, \< 0.001         9.93, \< 0.001
  VH, N (%)                  4 (2.6)           12 (5.2)         15 (26.3)         1.69, NS                   17.9, \< 0.001          6.64, \< 0.001
  Parkinsonism, N (%)        18 (11.8)         26 (11.4)        51 (89.5)         0.68, NS                   41.86, \< 0.001         66.64, \< 0.001
  RBD, N (%)                 17 (11.0)         9 (3.9)          22 (38.6)         0.34, 0.023                7.89, \< 0.001          17.47, \< 0.001
  DaTabN\*, N (%)            5 (35.7)          3 (27.3)         13 (72.2)         0.64, NS                   3.84, NS                10.8, 0.018
  Informer age, year         61.0 (12.6)       54.1 (10.2)      56.8 (12.4)       0.94, \< 0.001             0.96, 0.035             1.02, NS
  Informer education, year   10.0 (4.4)        12.1 (3.3)       11.2 (3.5)        1.12, 0.011                1.07, NS                0.91, NS

Odds ratio (OR) was Adjusted for Age. NDC, Non-demented control, including normal cognition and mild cognitive impairment; AD, Alzheimer's disease; DLB, dementia with Lewy bodies; NA, Not applicable; NS, Non-significance; CDR-SB, Sum of boxes of the Clinical Dementia Rating Scale; HAI-VSQ, Visuospatial function questionnaire in the History-based Artificial Intelligent Clinical Dementia Diagnostic System (HAICDDS); IADL, Instrumental Activities of Daily Living; MoCA, Montreal Cognitive Assessment; CASI, Cognitive Abilities Screening Instrument; NPI, Neuropsychiatric Inventory; VH, Visual hallucinations; RBD, REM sleep behavior disorder; DaTabN\*, Abnormal dopamine transporter imaging among eight ND, 12 AD, and 17 DLB participants.

Pearson correlation coefficients between age, education, gender, CDR-SB, IADL, CASI, MoCA, and NPI of different diagnostic tools for VSD are summarized in [Table 2](#T2){ref-type="table"}. The HAI-VSQ had weak to moderate correlation with MoCA-VS (*r* = -0.380, *p* \< 0.001) or CASI-Draw (*r* = -0.467, *p* \< 0.001). Furthermore, except for the non-correlation between HAI-VSQ with gender (*r* = -0.026, *p* \< 0.341), other parameters were significantly correlated. In contrast to HAI-VSQ, MoCA-VS (*r* = 0.234, *p* \< 0.001) and CASI-Draw (*r* = 0.187, *p* \< 0.001) were weakly correlated to gender. Compared to MoCA-VS or CASI-Draw, HAI-VSQ had the lowest correlation with age or education and the highest correlation with CDR-SB.

###### 

Point-Biserial correlation coefficients between age, education, gender, CDR-SB, IADL, CASI, MoCA, and NPI of different diagnostic tools for visuospatial dysfunction among all participants in NDC, AD, and DLB Groups.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
              Age             Education       Gender          CDR-SB          IADL            MoCA            CASI            NPI             HAI-VSQ         MoCA-VS         CASI-Draw
  ----------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  HAI-VSQ     *r* = 0.330\    *r* = −0.112\   *r* = −0.026\   *r* = 0.825\    *r* = −0.602\   *r* = −0.552\   *r* = −0.683\   *r* = 0.235\                    *r* = −0.380\   *r* = −0.467\
              *p* \< 0.001    *p* = 0.019     *p* = 0.341     *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001                    *p* \< 0.001    *p* \< 0.001

  MoCA-VS     *r* = −0.550\   *r* = 0.584\    *r* = 0.234\    *r* = −0.537\   *r* = 0.598\    *r* = 0.842\    *r* = 0.715\    *r* = −0.131\   *r* = −0.380\                   *r* = 0.599\
              *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* = 0.006     *p* \< 0.001                    *p* \< 0.001

  CASI-Draw   *r* = −0.396\   *r* = 0.424\    *r* = 0.187\    *r* = −0.612\   *r* = 0.565\    *r* = 0.687\    *r* = 0.786\    *r* = −0.140\   *r* = −0.467\   *r* = 0.599\    
              *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* \< 0.001    *p* = 0.003     *p* \< 0.001    *p* \< 0.001    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CDR-SB, Sum of boxes of the Clinical Dementia Rating Scale; IADL, Instrumental Activities of Daily Living; MoCA, Montreal Cognitive Assessment; CASI, Cognitive Abilities Screening Instrument; NPI, Neuropsychiatric Inventory; HAI-VSQ, Sum score of the visuospatial questionnaire in History-based Artificial Intelligent Clinical Dementia Diagnostic System (HAICDDS); MoCA-VS, Visuospatial domain in MoCA; CASI-Draw, Visuospatial domain in CASI.

The comparison of visuospatial subscales in HAI-VSQ, MoCA-VS, and CASI-Draw among NDC, AD, and DLB, the odds ratio (OR) adjusted for age, education, gender, and the cognitive state by CASI total score are summarized in [Table 3](#T3){ref-type="table"}. The HAI-VSQ significantly discriminated DLB from AD or NDC whereas MoCA-VS or CASI-Draw did not.

###### 

Comparison of visuospatial subscales in HAICDDS (HAI-VSQ), MoCA (MoCA-VS), and CASI (CASI-Draw) among NDC (*N* = 154), AD (*N* = 229), and DLB (*N* = 57) participants.

              NDC mean (SD)   AD mean (SD)   DLB mean (SD)   AD vs. NDC OR, *p*-value   DLB vs. NDC OR, *p*-value   DLB vs. AD OR, *p*-value
  ----------- --------------- -------------- --------------- -------------------------- --------------------------- --------------------------
  HAI-VSQ     0.4 (0.6)       2.0 (2.2)      3.3 (2.2)       2.79, \< 0.001             4.28, \< 0.001              1.48, \< 0.001
  MoCA-VS     2.5 (1.6)       0.5 (1.0)      0.4 (0.7)       0.81, NS                   0.70, NS                    0.96, NS
  CASI-Draw   8.6 (2.5)       4.9 (4.1)      4.3 (3.5)       1.25, 0.003                1.03, NS                    1.02, NS

Odds Ratio (OR) was Adjusted for Age, Education, Gender, and Cognitive State by CASI Total Score.

NDC, Non-demented control; AD, Alzheimer's disease; DLB, dementia with Lewy bodies; NA, Not applicable; NS, Non-significance; HAI-VSQ, Visuospatial function questionnaire in History-based Artificial Intelligent Clinical Dementia Diagnostic System (HAICDDS); MoCA-VS, Visuospatial domain in MoCA; CASI-Draw, Visuospatial domain in CASI.

Visuospatial subscales of HAI-VSQ (A), MoCA-VS (B), and CASI-Draw (C) in different stages of dementia with Lewy bodies (DLB) and non-DLB are summarized in [Figure 2](#F2){ref-type="fig"}. Among all participants, significantly increased HAI-VSQ (all *p* \< 0.001) and decreased CASI-Draw (all *p* \< 0.05) were noted as the severity of dementia increased. MoCA-VS was different in the CDR 0/0.5 stage compared to other stages (all *p* \< 0.001). Among DLB participants, HAI-VSQ showed significant differences in CDR 3 vs. CDR 2, CDR 3 vs. CDR 1, CDR 3 vs. CDR 0/0.5, and CDR 2 vs. CDR 0/0.5. CASI-Draw showed significant differences in CDR 0/0.5 vs. CDR 1, CDR 2, and CDR 3. MoCA-VS did not differentiate between any two stages according to CDR. Among non-DLB participants, significantly increased HAI-VSQ (all *p* \< 0.001) and decreased CASI-Draw (all *p* \< 0.05) were noted as the severity of dementia increased. Except for CDR 2 vs. CDR 3, significantly decreased MoCA-VS (all *p* \< 0.005) was noted as the severity of dementia increased.

![Visuospatial subscales of HAICDDS (HAI-VSQ, **A**), MoCA (MoCA-VS, **B**), and CASI (CASI-Draw, **C**) in different stages of dementia with Lewy bodies (DLB), non-DLB, and all participants. Participants with CDR 0 were classified only in the non-LBD group and all participants. **(A)** HAI-VSQ in different stages according to CDR. **(B)** MoCA-VS in different stages according to CDR. (1c) CASI-Draw in different stages according to CDR.](fnins-14-00044-g002){#F2}

Discussion {#S4}
==========

This study was a sub-study of the HAICDDS project, analyzing and comparing data between NDC, AD, and DLB groups with two main results. First, using HAI-VSQ, a cutoff score ≥ 2 discriminates VSD in DLB from NDC with high sensitivity (0.77), specificity (0.94), and AUC (0.91). To provide more objective evidence, we analyzed the correlation of the HAI-VSQ with dopamine transporter imaging among NDC and DLB groups and the result showed a high negative correlation of striatal background ratio (SBR) of dopamine transporter imaging with the HAI-VSQ with correlation coefficient -0.571 and *p* \< 0.001. These findings have provided additional evidence that the HAI-VSQ has high correlation with DLB because of abnormal dopamine transporter imaging being the indicative biomarker for the diagnosis of DLB. Therefore, we provided a simple tool that can help clinicians to detect DLB more easily at the bedside or in clinics. Additionally, HAI-VSQ is probably the first informant-based VSD questionnaire that includes not only visuospatial but also visuomotor questions. We found more severe VSD according to the questionnaire in patients with DLB compared to NDC or AD. In this study, one or more visuospatial or visuomotor symptoms were reported in 31.2% of NDC, and 81.7% of AD and 91.2% of DLB patients. In mild stages, symptoms were reported in 74.4% of AD and 80.8% of DLB patients in CDR = 0.5 or 1. These results are consistent with previous studies on VSD that showed common and early symptoms in AD as well as in DLB ([@B5]; [@B26]; [@B23]; [@B8]; [@B27]; [@B10]; [@B28]; [@B11]; [@B15]). More severe VSD in DLB according to the HAI-VSQ compared to AD is also consistent with results from previous studies ([@B23]; [@B27]; [@B15]).

Second, compared to MoCA-VS or CASI-Draw, HAI-VSQ had no correlation with gender and the lowest correlation with age and education. We considered this an important result because the current frequently-used dementia screening tools such as MoCA or CASI are too sensitive to age, gender, culture, and education. Therefore, a large variety of cut-off scores and adjustments are necessary for the screening of dementia or cognitive impairment when using these tools ([@B17]; [@B21]; [@B2]). Furthermore, HAI-VSQ had the highest correlation with CDR-SB which had the highest correlation with dementia severity compared to the MoCA-VS or CASI-Draw scales.

In addition to above-mentioned findings, after adjustment for age, education, gender, and cognitive state by CASI total score, HAI-VSQ was significantly different in DLB patient than in NDC (OR = 4.28, *p* \< 0.001) or AD patients (OR = 1.48, *p* \< 0.001), and between AD patients and NDC participants (OR = 2.79, *p* \< 0.001). MoCA-VS or CASI-Draw showed no significant differences. This finding underlines the clinical applicability of the HAI-VSQ for the discrimination of DLB from AD or NDC and of AD from NDC participants. This also indicates that the information acquired from caregivers may be more useful or at least as useful as the cognitive performance of patients because the caregivers directly face the caring problems which might result in a higher impact of VSD on them.

Finally, we want to address the important issue that commonly-used informant-based questionnaires for the screening of dementia or cognitive impairment from normal elderly including CDR, AD8, or IQCODE are lacking or have only a few questions regarding VSD ([@B12]; [@B20]; [@B9]; [@B24]). We are providing a simple informant-based visuospatial questionnaire for the clinical assessment of individuals with dementia. The purpose of our study was not using a cut-off score for the discrimination of patients with language dysfunction from normal people. Instead, we want to provide an easy way for clinicians to be aware of the visuospatial as well as visuomotor problems of patients with dementia due to AD or DLB.

There are several limitations to this study. First, the questionnaire is an original Taiwanese version. More precise and colloquial translations will be necessary when translating the questionnaire to other language versions although we have preliminarily translated the questionnaire to English. Second, our study was conducted in only three centers in Taiwan and the questionnaire contained only seven questions. The findings of different presentations of VSD may not be generalizable to all individuals with NDC, AD, or DLB. Third, the comparison among different groups in our study was retrospective and cross-sectional. Therefore, a causal relationship between VSD and the underlying pathophysiologies of AD or DLB could not be investigated.

Conclusion {#S5}
==========

In conclusion, our study showed that similar to our recently published language questionnaire (HAICDDS-Language) ([@B16]), the informant-based simple questionnaire was a practical screening tool and was more applicable than the visuospatial subscale of MoCA or CASI for the discrimination of NDC, AD, and DLB. We intend to design and validate several dementia-related simple questionnaires and hope that these rapid screening tools can be applied in clinical practice as well as in a registration platform for the screening of VSD as well as other cognitive dysfunctions. A further goal is to implement machine learning techniques to improve the accuracy and efficiency of these questionnaires.
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###### 

Composition of the visuospatial questionnaire in HAICDDS (HAI-VSQ).

  ----- -------------------------------------------------------------------------------------------------------------- -------- ---------------- ---------
  VS1   方向感變差了嗎?                                                                                                □不會    □會              
        Does he/she have trouble finding directions?                                                                   □ No     □ Yes            
  VS2   在熟悉的環境（例如：住家附近）會迷路嗎?                                                                        □ 不會   □ 會             
        Does he/she get lost in familiar surroundings, for example, the neighborhood?                                  □ No     □ Yes            
  VS3   會搞不清楚自己在哪裏嗎?                                                                                        □ 不會   □ 偶而           □ 常常
        Does he/she have trouble locating himself/herself?                                                             □ No     □ Occasionally   □ Often
  VS4   會「常常｣認錯人，例如：把兒子當成丈夫，把女兒當成姊妹嗎?                                                       □ 不會   □ 偶而           □ 常常
        Does he/she often recognize the wrong person, for example, recognizing son as husband or daughter as sister?   □ No     □ Occasionally   □ Often
  VS5   □走路、騎車或是開車的時候沒辦法直直走，常常偏到旁邊去嗎?                                                       □ 不會   □ 偶而           □ 常常
        Does he/she often deviate to one side during walking, riding, or driving on the road?                          □ No     □ Occasionally   □ Often
  VS6   沒辦法順利地開門，好像找不太到鑰匙孔或門把嗎?                                                                  □ 不會   □ 偶而           □ 常常
        Does he/she have difficulties in finding the keyhole or doorknob for opening the door?                         □ No     □ Occasionally   □ Often
  VS7   閱讀或是寫字變得困難嗎?                                                                                        □ 不會   □ 偶而           □ 常常
        Does he/she have difficulties in reading or writing?                                                           □ No     □ Occasionally   □ Often
  ----- -------------------------------------------------------------------------------------------------------------- -------- ---------------- ---------
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